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IFN-α-mediated Base Excision 
Repair Pathway Correlates with 
Antiviral Response Against 
Hepatitis B Virus Infection
Yong Li1, Yuchen Xia  2,3, Meifang Han1, Guang Chen1, Dake Zhang4, Wolfgang E. Thasler5, 
Ulrike Protzer  2,6 & Qin Ning1
Previous studies identified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA 
in the nucleus thus affecting its persistence. Interferon (IFN)-α treated chimpanzees and hepatitis C 
patients showed elevated APOBEC expression. We thus hypothesized that the responses to IFN-α 
treatment of chronic hepatitis B (CHB) patients is influenced by IFN-induced base excision repair (BER). 
CHB-treatment naïve patients, patients treated with PEGylated IFN-α, and patients with sequential 
treatment of Entecavior and PEGylated IFN-α were recruited. Blood and liver biopsy samples were 
collected before treatment and at treatment endpoint. BER genes were assessed by quantitative RT-
PCR. BER gene expression levels and IFN treatment responses were correlated in patient liver biopsies. 
APOBEC3A, -B, -C, -D/E, and-G mRNA levels were up-regulated in IFN-treated patients. APOBEC3A 
expression was significantly higher in IFN-responders than in non-responders. BER genes NEIL3 was 
down-regulated in IFN-treated patients. APOBEC3 and BER gene expression at treatment endpoints 
partially correlated with the corresponding absolute DNA level or degree of HBsAg and HBV DNA 
decline. Our study suggests that the expression of APOBEC3A positively correlates with IFN-treatment 
responses in CHB patients, while NEIL3 shows negative correlation. These genes may involve to IFN 
mediated viral suppression and serve as biomarkers for CHB disease management.
Hepatitis B remains a global health problem1, with an estimated 250–400 million people chronically infected 
with HBV worldwide2 at risk to develop end-stage liver disease such as HBV-induced liver failure, liver cirrhosis 
or hepatocellular carcinoma (HCC)3,4. Currently, there are two major classes of antivirals approved for the treat-
ment of CHB: oral nucleos(t)ide analogues and immunomodulatory agents including unmodified and PEGylated 
interferon-α (PegIFN-α). These treatments can control virus replication, minimize liver damage and reduce the 
risk of HBV associated liver disease. Unfortunately, none of the available treatments can efficiently cure hepatitis 
B, because of the persistence of HBV covalently closed circular DNA (cccDNA) in the nucleus of infected cells5.
Nucleos(t)ide analogues inhibit HBV reverse transcription taking place before HBV egress and have no direct 
effect on the nuclear viral transcriptional template, the cccDNA. IFN-α has been a backbone of therapy of chronic 
hepatitis B (CHB)6. Dosing, however, is limited by side effects and response rates are less than 30% in CHB 
patients4. Although the molecular mechanism remained elusive, it remains the only drug leading to viral clearance7. 
In different experimental models, IFN-α induced products have been shown to restrict HBV infection at multiple 
steps8,9. Recently, it has been shown that in HBV infection cell culture models, induction of APOBEC3A and 
the base excision repair (BER) pathway by IFN-α or T-cell cytokines is essential for cccDNA decreasing8,10,11. 
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IFN-α induced APOBEC3A deaminates the nuclear HBV DNA minus strand, resulting uracil-containing 
DNA that recognized, cleaved and degraded by cellular BER enzymes. Although APOBEC3A was found to be 
up-regulated in IFN-α treated chimpanzee and chronic hepatitis C patient livers10, the expression profiles of 
APOBEC3 family members as well as BER genes and their correlation with IFN-α treatment response in patients 
with CHB has not been addressed. In this study, we report that in particular the expression levels of DNA-editing 
enzymes APOBEC3A, but also BER gene NEIL3 correlate with response to IFN treatment in CHB patients. These 
genes indicate the molecular pathways involved in HBV cure but may also serve as biomarkers for CHB disease 
management.
Results
IFN-α treatment induces APOBEC3 mRNA expression in liver samples from CHB patients. It 
is well acknowledged that IFN-α induces APOBEC3 family cytidine deaminases in cell culture models10,12, but 
whether IFN-α can induce APOBEC3 gene in liver biopsies from patients has not been conclusively studied. Due 
to the lack of available CHB patient data, we first did a meta analysis of two published datasets from hepatitis 
C patients13,14. In these two studies, liver biopsies of different individuals before and under interferon therapy 
were analyzed using microarray based expression profiling. As shown in Fig. 1A, among the APOBEC3 family 
members, APOBEC3A, APOBEC3B and APOBEC3C demonstrate increased expression levels in under therapy 
samples with fold changes at 14, 77.4 and 2.8 respectively. (p after Bonferroni correction <0.05) when comparing 
their expression before and under IFN therapy.
To determine whether similar expression patterns can be observed in CHB patients under IFN treatment, 
liver biopsies from CHB patients with or without IFN treatment were collected and qRT-PCR was performed 
(Supplementary Table 1). Hereby, we found that APOBEC3A, -B,-C,-DE, and -G mRNA expression were signif-
icantly induced in livers of patients treated with IFN-α compared to treatment-naïve patients or OSST patients1 
before IFN-α treatment (Fig. 1B), while APOBEC3F and APOBEC3H were only up-regulated in three patients 
(Fig. 1C). We also analyzed paired samples only as shown in Fig. S1, APOBEC3A, -B and -G mRNA expression 
was significantly induced after IFN-α treatment. These findings indicate that APOBEC3 deaminases are regulated 
in livers of CHB patients following IFN-α treatment.
Expression of APOBEC3A mRNA correlates with response to interferon treatment. The next 
question we wanted to answer is whether the expression of APOBEC3 deaminases correlate with the outcome 
of IFN-α therapy. To answer that question, we separated and compared the gene expression level of responders 
and non-responders to IFN-α treatment (response to therapy is defined as HBV DNA level <1000 copies/ml 
with HBeAg or HBsAg seroconversion or HBsAg decline >1Log10IU/ml at treatment endpoint). Interestingly, 
APOBEC3A and APOBEC3B mRNA levels were significantly higher in responders than in non-responders 
(Fig. 2A). While there was a tendency for increased APOBEC3C, APOBEC3G and APOBEC3H expression, 
expression of the other APOBEC3 genes did not differ between responders and non-responders (Fig. 2B). This 
indicated a role of APOBEC3 deaminases, particularly APOBEC3A and APOBEC3B, for the outcome of inter-
feron treatment.
To further investigate whether APOBEC3 gene expression correlated with viral suppression, correlations of 
their expression and HBV biomarkers were studied. Since OSST patients’ HBV DNA were all below detection 
level before IFN therapy, antiviral response of only patients with IFN monotherapy were evaluated. Correlations 
between APOBEC3 expression levels and HBsAg or HBV DNA decline (Log week 0 − Log week 48/96) (Fig. S2). 
Hereby, APOBEC3F mRNA levels at treatment endpoint significantly correlated with the degree of HBsAg decline 
(Fig. S2A) and that of APOBEC3C with HBV DNA decline (Fig. S2B), while APOBEC3A, -C, and -G showed a 
trend for correlation. At treatment endpoints, APOBEC3 gene mRNA level partially correlated with correspond-
ing HBsAg or HBV DNA levels (Fig. 3, given in a Log10 scale). While APOBEC3A and -C mRNA level at treat-
ment endpoints negatively correlated with HBsAg levels (p = 0.09 and p = 0.04, respectively), other APOBEC3 
genes show modest or not correlation (Fig. 3A). Similar correlations were found between APOBEC3 mRNA levels 
and viremia at end of treatment (Fig. 3B). Higher HBV DNA associated with lower hepatic APOBEC3A and –C 
expression levels (p = 0.08 and p = 0.03, respectively).
Together, these data from clinical setting of patients suggest that higher expression of in particular APOBEC3A 
and -C indicate a better response to IFN-α during CHB treatment.
IFN-α treatment regulates BER enzymes in liver samples from CHB patients. Because deami-
nase expression on its own will not be sufficient to lead to HBV DNA degradation or loss, we assessed the expres-
sion of other genes involved in the DNA BER pathway in liver samples from IFN-α treated and non-treated CHB 
patients. Interestingly, we found methyl-CpG binding domain 4 DNA glycosylase (MBD4), APEX nuclease (APE) 
and 8-Oxoguanine DNA Glycosylase (OGG) were induced, while Nei-like DNA glycosylase (NEIL)3 was reduced 
in liver samples from patients after IFN-α treatment (Fig. 4A). Thymine DNA glycosylase (TDG), NEIL1, NEIL2, 
N-methylpurine DNA glycosylase (AAG), single-strand-selective mono functional uracil-DNA glycosylase 1 
(SMUG1), uracil DNA glycosylase (UNG) and DNA-(cytosine-C5)-methyl transferase (C5MTF) were expressed 
at comparable levels between naïve- and IFN-α-treated CHB patients (Fig. 4B). As expected, paired liver biopsy 
samples before and after IFN treatment showed similar pattern as shown in Fig. S3: MBD4, APE and OGG were 
up-regulated while NEIL3 was down-regulated. However, TDG and NEIL2 were also regulated in this cohort.
Comparing responders to non-responders to IFN-α treatment, NEIL3 and TDG were down-regulated in 
responders. AAG, SMUG1, OGG and APE mRNA levels showed a tendency to be up-regulated in responders, 
while NEIL2 and MBD4 mRNA levels showed a tendency to be down-regulated in responders (Fig. S4).
To confirm the results of BER enzyme expression from CHB patient samples, PHH and differentiated HepaRG 
cells were in vitro infected with HBV and then treated with IFN-α. As shown in Fig. 5, NEIL3 expression was 
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down-regulated in PHH and HepaRG cells following IFN-α treatment (Fig. 5), while TDG was down-regulated 
in PHH (Fig. 5A), but up-regulated in HepaRG cells (Fig. 5B). In addition, AAG was down-regulated in PHH but 
up-regulated in HepaRG cells with IFN-α treatment, while NEIL1 and OGG was down-regulated in both models. 
UNG and MBD4 were upregulated in HepaRG cells but not in PHH. In summary, besides down-regulation of 
NEIL3 no distinct regulation of enzymes involved in BER was detected.
BER enzymes expression correlated with virologic response in PegIFN-α treated CHB 
patients. To further investigate whether the expression of enzymes involved in BER correlated with IFN-α 
treatment response, BER gene expression and HBV markers determined at treatment endpoint were correlated. 
In patients undergoing IFN-α mono-treatment, hepatic NEIL2 and NEIL3 mRNA levels at treatment endpoints 
significantly correlated positively to corresponding serum HBsAg levels (Fig. 6A) and HBV viremia (Fig. 6B). 
AAG and OGG mRNA negatively correlated with HBsAg levels (Fig. 6A) but not with HBV DNA. (Fig. 6B). 
Interestingly, none of these BER genes showed a significant correlation to HBsAg or HBV DNA decline (Fig. S5). 
Considering IFN responders showed lower amount of NEIL2 and TDG in their livers at end of treatment (Fig. S4), 
Figure 1. mRNA expression of APOBEC3 family members in liver biopsies of patients treated with IFN. (A) 
Meta analysis of transcription levels of APOBEC3 family members, in two studies reporting hepatitis C patients 
under IFN treatment13,14. The top scaled color bar indicates the relative gene expression level, and the dark and 
light blue bars illustrate two groups of patients: under and before therapy. In the heatmap, each column contains 
the data from one patient, and each square shows the gene expression level in a specific individual. All changes 
had FDR(BH) <0.01 and p after Bonferroni correction <0.05. More details for all six genes are summarized 
in Supplementary Table 3. (B,C) Total RNA from liver biopsies of naïve- or IFN-α-treated CHB patients were 
extracted. After reverse transcription, mRNA expression levels of APOBEC3A, -B, -C, -D/E, -G (B), -F, and -H 
(C) were quantified and normalized to GAPDH mRNA. Student’s t test was used to compare the two groups. 
*P < 0.05; N.S. no significance.
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these findings indicate that BER may play a role in controlling HBV and in response to IFN-α treatment in CHB 
patients, and some of the genes have a potential for use as IFN treatment response indicators. Their roles in con-
trolling HBV infection need to be further studied.
Figure 2. Comparison of APOBEC3 gene expression levels between responders and non-responders. Relative 
expression level of hepatic APOBEC3A (A), or APOBEC3B, -C, -DE, -F, -G, -H mRNA (B) normalized to 
GAPDH were compared in responders and non-responders at the end of PegIFN-α treatment. Student’s t test or 
Mann Whitney U test was used to compare the two groups. *P < 0.05; N.S., no significance.
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Discussion
IFN-α has been reported to induce the BER pathway leading to the depletion of the HBV persistent form, the 
cccDNA, in vitro10,15. In this study, we found that APOBEC3 family deaminases were up-regulated in liver biop-
sies from CHB patients treated with IFN-α compared to a treatment-naïve group. This finding corresponds to 
previously published data from liver samples of chimpanzees and chronic hepatitis C patients undergoing IFN-α 
treatment10. Importantly, we further found that APOBEC3A and APOBEC3B mRNA expression in responders 
to IFN therapy was significantly higher than in non-responders. Further more, APOBEC3A expression is neg-
atively correlate with HBV infection markers at treatment endpoint. Thus, higher APOBEC3A levels at treat-
ment endpoints suggests a better response to IFN-α during HBV treatment. Our results, to some extent, were in 
Figure 3. Correlation between APOBEC3 gene expression and HBV markers. Correlations of hepatic 
APOBEC3 gene expression at treatment endpoint with HBsAg (A) or HBV DNA (B) in the patient serum at 
treatment endpoint were evaluated using Pearson correlation. Log 10 values of HBsAg or HBV DNA were 
bloted.
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agreement with a study on HCV:APOBEC3A was up-regulated in early responders but not in non-responders in 
HCV patients16. Although the number of clinical samples in our study is small due to limited availability of liver 
biopsies in CHB patients under or after therapy, APOBEC3A displayed a trend for positive correlation with the 
degree of HBsAg and HBV DNA decline. In this scenario, it suggested that APOBEC3A plays an important role 
in the response to IFN-α.
While detection of deaminated cccDNA from patients’ liver biopsies would be ideal, we unfortunately could 
not detect cccDNA in the liver biopsies available in our study. This might be due to a variety of reasons. First, 
to increase specificity, our cccDNA qPCR amplicon is rather long (about 1kB)17,18, and thus fragmentation of 
DNA during tissue fixation or extraction very likely affects the PCR reaction. Secondly, after long-term IFN-α 
Figure 4. Expression of BER genes in liver biopsies from CHB patients. Total RNA from liver biopsies of 
naïve or IFN-α-treated CHB patients were extracted. After reverse transcription, (A) NEIL3 and TDG mRNA 
levels and (B) NEIL1, NEIL2, MBD4, AAG, OGG, SMUG1, UNG, and APE expression levels were quantified 
and normalized to GAPDH mRNA. Student’s t test or Mann Whitney U test test was used to compare the two 
groups.*P < 0.05; N.S., no significance.
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Figure 5. Interferon regulation of BER genes in cell culture. PHH (A) and differentiated HepaRG cells (B) were 
infected with HBV at MOI 200 virions/cell. After 7 days, cells were treated with 1000 IU/ml IFN-α. Total RNA 
from PHH and HepaRG cells were extracted after 18 hours (A) or at indicated time points (B). After reverse 
transcription, selected mRNAs of enzymes involved in BER were quantified and normalized to GAPDH mRNA. 
*P < 0.05; #P < 0.01; N.S., no significance. Student’s t test was used to compare the untreated (donor1/2-) and 
treated (donor1/2+) PHH. ANOVA was used to compare gene expression at different time points and baseline 
in HepaRG cells.
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treatment lasting 48 or even 96 weeks, the deaminated cccDNA has very likely already been degraded or repaired 
by cellular enzymes.
Although cccDNA decreasing could not be proven in this study, HBV DNA and in particular HBsAg decline 
made a loss of cccDNA very likely. Previous clinical investigations reported by Petersen et al. had shown that 
hepatic cccDNA level positively correlated with corresponding HBsAg and HBV DNA levels7. We therefore 
assessed whether APOBEC3 family gene expression correlated with HBV clinical markers. In addition, we made 
Figure 6. Correlation between BER gene expression and corresponding viral markers. Hepatic expression of 
BER enzymes at treatment endpoint were correlated with HBsAg (A) or HBV DNA (B) titers in the serum at 
treatment endpoint. Correlations between BER gene expression and viral markers were tested using Pearson 
correlation. Log 10 values of HBsAg or HBV DNA were bloted.
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an effort to explore how viral markers correlated to the expression of enzymes involved in BER. Interestingly, not 
only nuclear APOBEC3A seemed to be of importance, but also other cytoplasmic APOBEC3 family members 
were upregulated in IFN-treated patients, and APOBEC3C and F mRNA levels correlated with the decline of 
HBV DNA and HBsAg, respectively. It has been reported that APOBEC3F can impact HBV replication in the 
cytoplasm and may contribute to the non-cytolytic clearance of HBV12,19. In addition, Köck et al. reported that 
transfection of HepG2 cells with a plasmid encoding the APOBEC3C protein resulted in abundant G→A muta-
tions in the majority of newly formed HBV genomes20.
APOBEC3 A or B proteins are important to induce HBV cccDNA deamination but are not sufficient to lead 
to viral clearance15. To investigate other effectors induced by IFN-α, we checked ten genes involved in the DNA 
BER pathway and identified two potential candidates. We found that both NEIL3 and TDG mRNA expression 
were down-regulated in liver samples from patient under IFN-α treatment. TDG is a member of the mismatch 
uracil glycosylase branch of the monofunctional uracil DNA glycosylase superfamily. TDG can excise uracil and 
result in abasic site formation in DNA strands, which may subsequently be processed by the BER machinery21,22. 
NEIL3 has recently been identified as potential binding partner for oxidized cytosine derivatives23. It has been 
reported that a variation trend of TDG and NEIL3 is consistent in cell models24, and TDG has a synergistic effect 
on accumulation of genomic 5-formylcytosine and 5-carboxylcytosine mediated by NEIL3. Our results in clinical 
samples were in accordance with these findings. We found that NEIL3 and NEIL2 at treatment endpoints was 
positively correlated with remaining HBsAg and HBV DNA levels. Our results indicated that a part of BER genes, 
such as NEIL3 and TDG, may represent potential factors related to IFN-α response in HBV treatment.
A previous study showed changes in BER gene mRNA levels in normal liver tissues and tumor cell lines treated 
with IFN-α12. In an effort to confirm our in vivo findings in HBV infected cells, differentiated HepaRG cells and 
PHH were exploited, which are widely used for a better understanding of hepatic disease pathogenesis25,26. NEIL3 
was significantly down-regulated by IFN-α in both PHH and HepaRG cells, while TDG was down-regulated only 
in PHH in our study. The different TDG expression pattern in two cells may due to the transformed nature or 
influence of biliary like cells in HepaRG cultures27. Why these two genes were down-regulated and not induced 
as one may expect in a first instance may be explained by their involvement in viral DNA repair. Once deami-
nated, nuclear HBV DNA may undergo two fates: either it is repaired or it is degraded. Thus, down-regulation of 
TDG and NEIL3 maybe consistent with less cccDNA repair and thus more cccDNA degradation. However, more 
detailed mechanistic studies will be needed to address this point.
Taken together, our study provides new insights into the IFN-α-mediated regulation of BER genes in livers 
of CHB patients under IFN-α treatment. Response to IFN-α treatment in CHB patients seems to be associated 
with a distinct differential intra-hepatic BER gene expression profile, where positive responses are associated with 
higher levels of hepatic APOBEC3A and lower level of NEIL3 and TDG. However, the exact biological mecha-
nisms underlying the influence of BER genes in IFN-α treatment response remain to be determined. Further 
studies, both in vivo and in cell culture, may provide a better understanding of the role of BER in antiviral strate-
gies targeting HBV that can be employed to optimize antiviral treatment.
Methods
Study subjects, clinical samples and study design. This research was performed according to the 
ethical guidelines of the 1975 Declaration of Helsinki and received prior approval from the Institutional Review 
Boards of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written 
informed consents from the patients were obtained prior to inclusion in the study. Sixteen naïve CHB patients 
were recruited from 2010 through 2011 at the Tongji Hospital affiliated to Huazhong University of Science and 
Technology in Wuhan, China. Inclusion criteria for naïve CHB patients in the study were HBV DNA level > 104 
copies/ml and HBeAg positivity. Six patients who didn’t receive any treatment were used as a control group 
(Patient #1–6, shown in Supplementary Table 1). Of the IFN-α monotherapy patients (patient #7–16, shown in 
Supplementary Table 1) receiving treatment with PegIFN-α2a (Pegasys, Roche, Germany) 180 µg once a week for 
24 weeks. At 24 weeks, patients with initial response (HBsAg less than1500 IU/ml and HBV DNA decline larger 
than 1Log10 copies/ml) continued PegIFN-α therapy until week 48 (Patient #11, 12, 13, 14). Remianing patients 
continued PegIFN-α therapy until week 96 (Patient #7, 8, 9, 10, 15, 16). Blood samples of IFN treated patients 
were collected at baseline and at the end of treatment. Liver samples of PegIFN-α treated patients were addition-
ally collected at treatment endpoints. Response to IFN-α treatment was defined as HBV DNA level <1000 copies/
ml with HBeAg or HBsAg seroconversion or HBsAg decline>1Log10IU/ml at treatment endpoint. Patients not 
meeting these criteria were classified as non-responders.
Seven paired liver biopsy samples were from The Optimising HBeAg Seroconversion in HBeAg-positive CHB 
patients with combination and Sequential Treatment of PegIFN alfa-2a and ETV (OSST) study1. Patients aged 
18–65 years who were HBeAg-positive prior to initiation of ETV treatment, had received ETV treatment for ⩾12 
months, had been positive for HBsAg for ⩾6 months prior to enrolment and who had serum HBV DNA ⩽1000 
copies/ml and serum HBeAg <100 PEIU/ml followed PegIFN-α therapy 180 μg/week for 48 weeks.
Characteristics of the patients are presented in Supplementary Table 1.
Microarray analysis. GSE17183 and GSE38598 datasets curated by Insilco DB28 was used for identifica-
tion of over-expressed genes after IFN therapy in HCV patients. For 44 samples in under therapy group, 42 
were from GSE17183 and the rest 2 (GSM945917, GSM945916) were retrieved from GSE38598 dataset. All 42 
control samples were collected from GSE17183. The analysis was performed on GENE-E platform (http://www.
broadinstitute.org/cancer/software/GENE-E/), using the SCAN method for data normalization. Fold changes of 
APOBEC3 family members between under therapy and before therapy groups were compared to determine if 
they were differentially expressed. For each gene, the significance of expression difference was estimated by a t test 
(p-value), and it then corrected for multiple hypotheses testing by computing the false discovery rate (FDR) and 
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the family-wise error rate (FWER). The FDR(BH) indicated the FDR value was estimated using the Benjamini 
and Hochberg procedure29.
Markers characterizing HBV infection. HBsAg, HBeAg and HBV DNA levels were measured at a central 
laboratory with the ARCHITECT HBsAg assay (Abbott Laboratories, Lake Forest, IL, USA), AxSYM HBe 2.0 
assay (Abbott), and either a standard generic HBV DNA assay (ACON Biotech Co. Ltd, Hangzhou, China) or 
the COBAS TaqMan HBV Test (Roche Molecular Diagnostics, Pleasanton, CA, USA). Anti-HBs and anti-HBe 
were assessed by ARCHITECT qualitative assays (Abbott).Alanine aminotransferase (ALT) was measured using 
a Hitachi Model 7600 Series Automatic Analyzer (Hitachi, Tokyo, Japan).
Cell cultures, HBV infection and IFN-α treatments. Cell culture, HepaRG cell differentiation and HBV 
infection with concentrated supernatant from HepAD38 cells was performed as described10. Primary human 
hepatocytes (PHH) were isolated from surgical liver specimens after informed consent of patients undergoing 
metastasis resection and seeded onto plastic dishes coated with collagen type IV30. Tissue samples and annotated 
data were obtained and experimental procedures were performed within the framework of the non-profit foun-
dation Human Tissue & Cell Research (HTCR). PHH and differentiated HepaRG cells were infected with HBV 
at MOI of 200 DNA-containing, enveloped virus particles/cell. After 7 days, cells were treated with 1000 IU/ml 
IFN-α (Referon-A, Roche) for indicated time periods.
qRT-PCR. RNA from liver biopsies was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and 
reverse-transcribed into cDNA with QPK201T reverse transcriptase (Toyobo, Tokyo, Japan). RNA from cultured 
cells was extracted using NucleoSpin® RNA II kit (Macherey Nagel, Düren, Germany) and reverse-transcribed 
with the Superscript III Reverse Transcription kit (Invitrogen, Carlsbad, USA) according to manufacturer’s 
instructions. Expression levels were quantified by qRT-PCR performed on a 7500 HT qRT-PCR system (Applied 
Biosystems, Life Technologies, Darmstadt, Germany) or on a LightCycler™ system (Roche Diagnostics, Basel, 
Switzerland) and analyzed by the second derivative maximum method that includes both normalization to the 
reference genes and primer efficiency.
RNA from liver biopsies and cultured cells was extracted, reverse transcribed and analyzed by qPCR 
(details see Supplementary Methods). Relative mRNA levels of all target genes were normalized to GAPDH 
house-keeping genes. The primers of target genes are listed in Supplementary Table 2.
Statistical analysis. The results were analyzed by the Student’s t test, Mann Whitney U test or ANOVA 
where appropriate. Distribution of the samples was evaluated by Kolmogorv- Smirnov test. The correlation of 
target gene and HBV clinical markers was processed by Pearson correlation. All statistical analyses were carried 
out with SPSS v.11 (SPSS, Chicago USA). P value of less than 0.05 was considered statistically significant.
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